Antibiotic resistance in the ICU: Clinical and cost aspects

Netherlands Journal of Critical Care

Volumn 12, Issue 1, 2008, Pages 20-25

  Vandijck, D M ^a,b   Depuydt, P O ^a   Blot, S I ^a,b,c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY COLLEGE GHENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; IMIPENEM; LINEZOLID; MEROPENEM; METICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BUDGET; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL INFECTION; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 59849114730     PISSN: 15693511     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Fleming A. Twentieth-century changes in the treatment of septic infections. N Engl J Med 1953;248:1037-1045.
2. Talbot GH, Bradley J, Edwards JE, Jr., Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-668.
3. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003;36:1433-1437.
4. Vandijck DM, Decruyenaere JM, Labeau SO, Depaemelaere M, Blot SI. Economic impact of catheter-related sepsis in the intensive care unit. ICU Management 2007;7:10.
5. Blot S, Depuydt P, Vandewoude K, De Bacquer D. Measuring the impact of multidrug resistance in nosocomial infection. Curr Opin Infect Dis 2007;20:391-396.
6. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002;162:2229-2235.
7. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-686.
8. Meyer E, Schwab F, Gastmeier P, Rueden H, Daschner FD. Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): a summary of the data from 2001 through 2004. Infection 2006;34:303-309.
9. Pascual A, Perea E, Alvarez M, Casal M, Garcia de Lomas J, Garcia Rodriguez JA, et al. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis. Diagn Microbiol Infect Dis 2007;57:195-200.
10. Turner PJ. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002). Diagn Microbiol Infect Dis 2005;51:281-289.
11. Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis 2006;56:367-372.
12. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999;160:608-613.
13. de Kraker M, van de Sande-Bruinsma N. Trends in antimicrobial resistance in Europe: update of EARSS results. Euro Surveill 2007;12:E070315 070313.
14. Hanberger H, Diekema D, Fluit A, Jones R, Struelens M, Spencer R, et al. Surveillance of antibiotic resistance in European ICUs. J Hosp Infect 2001;48:161-176.
15. Suetens C, Morales I, Savey A, Palomar M, Hiesmayr M, Lepape A, et al. European surveillance of ICU-acquired infections (HELICS-ICU): methods and main results. J Hosp Infect 2007;65 Suppl 2:171-173.
16. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999;20:303-316.
17. Bonten MJ, Mascini EM. The hidden faces of the epidemiology of antibiotic resistance. Intensive Care Med 2003;29:1-2.
18. McGowan JE, Jr. Is antimicrobial resistance in hospital microorganisms related to antibiotic use? Bull N Y Acad Med 1987;63:253-268.
19. Donskey CJ. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis 2006;43 Suppl 2:S62-69.
20. Mutlu GM, Wunderink RG. Severe pseudomonal infections. Curr Opin Crit Care 2006;12:458-463.
21. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358:135-138.
22. Weigel LM, Donlan RM, Shin DH, Jensen B, Clark NC, McDougal LK, et al. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007;51:231-238.
23. Vollaard EJ, Clasener HA. Colonization resistance. Antimicrob Agents Chemother 1994;38:409-414.
24. Carlet J, Ben Ali A, Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004;17:309-316.
25. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004;3:14.
26. Hoste EA, Vandijck DM, Van Holder RC, De Waele JJ, Lameire NH, Claus S, et al. Health Implications of Antimicrobial-Resistance in Bloodstream Infection Patients with Acute Kidney Injury. Infect Control Hosp Epidemiol 2007;28:1107-1110.
27. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485.
28. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:639-644.
29. Archibald L, Phillips L, Monnet D, McGowan JE, Jr., Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-215.
30. Fridkin SK, Welbel SF, Weinstein RA. Magnitude and prevention of nosocomial infections in the intensive care unit. Infect Dis Clin North Am 1997;11:479-496.
31. Weinstein RA. Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics. Emerg Infect Dis 2001;7:188-192.
32. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001;134:298-314.
33. McGowan JE, Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983;5:1033-1048.
34. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337:441-446.
35. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis 1992;15:37S-42S.
36. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000;132:621-630.
37. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. Jama 2003;290:2588-2598.
38. Jarvis WR, Edwards JR, Culver DH, Hughes JM, Horan T, Emori TG, et al. Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Am J Med 1991;91:185S-191S.
39. Gold HS, Moellering RC, Jr. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-1453.
40. Vandijck DM, Blot SI, Decruyenaere JM. Reduction of blood culture contamination rate by an educational intervention. Clin Microbiol Infect 2007;13:109.
41. Daschner F. Nosocomial infections in intensive care units. Intensive Care Med 1985;11:284-287.
42. Blot S, Vandewoude K. Early detection of systemic infections. Acta Clin Belg 2004;59:20-23.
43. Vandijck D, Decruyenaere JM, Blot SI. The value of sepsis definitions in daily ICU-practice. Acta Clin Belg 2006;61:220-226.
44. Vandijck DM, Hoste EA, Blot SI, Depuydt PO, Peleman RA, Decruyenaere JM. Dynamics of C-reactive Protein and White Blood Cell Count in Critically Ill Patients with Nosocomial Gram-positive vs. Gram-negative Bacteremia: A Historical Cohort Study. BMC Infect Dis 2007;7:106.
45. Blot SI. Limiting the Attributable Mortality of Nosocomial Infection and Multidrug Resistance in Intensive Care Units. Clin Microbiol Infect 2008; 14: 8-13.
46. Blot S, Depuydt P, Vogelaers D, Decruyenaere J, De Waele J, Hoste E, et al. Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit. Infect Control Hosp Epidemiol 2005;26:575-579.
47. Depuydt PO, Blot SI, Benoit DD, Claeys GW, Verschraegen GL, Vandewoude KH, et al. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit. Crit Care Med 2006;34:653-659.
48. Michel F, Franceschini B, Berger P, Arnal JM, Gainnier M, Sainty JM, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest 2005;127:589-597.
49. Bouza E, Munoz P, Burillo A, Lopez-Rodriguez J, Fernandez-Perez C, Perez MJ, et al. The challenge of anticipating catheter tip colonization in major heart surgery patients in the intensive care unit: are surface cultures useful? Crit Care Med 2005;33:1953-1960.
50. Vandijck DM, Annemans L, Oeyen S, Blot SI, Decruyenaere JM. Cost-effectiveness in critical care. ICU Management 2007;7:6-8.
51. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001;29:N114-120.
52. Vandijck DM, Blot SI, Decruyenaere JM, Vanholder RC, De Waele JJ, Lameire NH, et al. Costs and Length of Stay Associated with Antimicrobial-resistance in Acute Kidney Injury Patients with Bloodstream Infection. Acta Clin Belg 2008;in press.
53. Das I, O'Connell N, Lambert P. Epidemiology, clinical and laboratory characteristics of Staphylococcus aureus bacteraemia in a university hospital in UK. J Hosp Infect 2007;65:117-123.
54. Zahar JR, Clec'h C, Tafflet M, Garrouste-Orgeas M, Jamali S, Mourvillier B, et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis 2005;41:1224-1231.
55. Myny D, Depuydt P, Colardyn F, Blot S. Ventilator-associated pneumonia in a tertiary care ICU: analysis of risk factors for acquisition and mortality. Acta Clin Belg 2005;60:114-121.
56. Peres-Bota D, Rodriguez H, Dimopoulos G, DaRos A, Melot C, Struelens MJ, et al. Are infections due to resistant pathogens associated with a worse outcome in critically ill patients? J Infect 2003;47:307-316.
57. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-1177.
58. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-59.
59. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41:327-333.
60. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001;135:484-492.
61. Clark NM, Patterson J, Lynch JP, 3rd. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003;9:413-423.
62. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179.
63. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003;37:745-751.
64. Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J. Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia. Intensive Care Med 2006;32:1970-1978.
65. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 2005;11:68-74.
66. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 2003;29:471-475.
67. Blot SI, Depuydt P, Annemans L, Benoit D, Hoste E, De Waele JJ, et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis 2005;41:1591-1598.
68. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162:2223-2228.
69. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999;159:1127-1132.
70. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. Jama 1999;282:1745-1751.
71. Struelens MJ, Denis O. Can we control the spread of antibiotic-resistant nosocomial pathogens? The methicillin-resistant Staphylococcus aureus paradigm. Curr Opin Infect Dis 2006;19:321-322.
72. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26:166-174.
73. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 2006;10:R97.
74. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999;20:408-411.
75. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 2004;38:1377-1382.
76. McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004;25:425-430.
77. Depuydt P, Benoit D, Vogelaers D, Claeys G, Verschraegen G, Vandewoude K, et al. Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures. Intensive Care Med 2006;32:1773-1781.
78. Depuydt P, Blot S. Antibiotic therapy for ventilator-associated pneumonia: de-escalation in the real world. Crit Care Med 2007;35:632-633.
79. Colardyn F. Appropriate and timely empirical antimicrobial treatment of icu infections - a role for carbapenems. Acta Clin Belg 2005;60:51-62.